NovoCure (NVCR) Earnings Date, Estimates & Call Transcripts $29.85 +9.81 (+48.95%) (As of 12/2/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NovoCure Latest Earnings SummaryUpcoming Q4 Earnings DateFeb. 27EstimatedActual EPS (Oct. 30) -$0.28 Beat By $0.06 Consensus EPS (Oct. 30) -$0.34 NovoCure issued Q3 2024 earnings on October 30, 2024, reporting an EPS of -$0.28, which topped analysts' consensus estimates of -$0.34 by $0.06. Quarterly revenue rose 21.8% year-over-year to $155.10 million, above analyst estimates of $143.95 million. With a trailing EPS of -$1.40, NovoCure's earnings are expected to decrease next year, from ($1.31) to ($1.58) per share. Conference Call TranscriptConference Call AudioEarnings Press ReleaseEarnings Slide DeckSEC 10-Q/10-K FilingPowered by NVCR Upcoming EarningsNovoCure's next earnings date is estimated for Thursday, February 27, 2025, based off prior year's reporting schedules. Get NovoCure Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NovoCure and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNVCR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NVCR Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. NovoCure Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20243-$0.52-$0.36-$0.41Q2 20243-$0.51-$0.37-$0.43Q3 20243-$0.49-$0.38-$0.42Q4 20243-$0.39-$0.31-$0.35FY 202412-$1.91-$1.42-$1.61Q1 20251-$0.30-$0.30-$0.30Q2 20251-$0.31-$0.31-$0.31Q3 20251-$0.32-$0.32-$0.32Q4 20251-$0.35-$0.35-$0.35FY 20254($1.28)($1.28)($1.28) NovoCure Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 2/27/2025(Estimated)-------10/30/2024Q3 2024-$0.34-$0.28+$0.06-$0.28$143.95M$155.10M7/25/2024Q2 2024-$0.40-$0.31+$0.09-$0.31$135.83M$150.40M5/2/2024Q1 2024-$0.43-$0.36+$0.07-$0.36$131.44M$138.50M2/22/2024Q4 2023-$0.53-$0.45+$0.08-$0.45$133.80M$133.80M10/26/2023Q3 2023-$0.51-$0.46+$0.05-$0.46$128.75M$127.30M7/27/2023Q2 2023-$0.50-$0.54 -$0.04-$0.54$124.25M$126.05M Get the Latest News and Ratings for NVCR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. 5/4/2023Q1 2023-$0.36-$0.50 -$0.14-$0.50$127.93M$122.20M2/23/2023Q4 2022-$0.32-$0.36 -$0.04-$0.36$127.20M$128.43M NovoCure Earnings - Frequently Asked Questions When is NovoCure's earnings date? NovoCure has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates. Learn more on NVCR's earnings history. Did NovoCure beat their earnings estimates last quarter? In the previous quarter, NovoCure (NASDAQ:NVCR) reported ($0.28) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.34) by $0.06. Learn more on analysts' earnings estimate vs. NVCR's actual earnings. How can I listen to NovoCure's earnings conference call? The conference call for NovoCure's latest earnings report can be listened to online. Listen to Conference Call How can I read NovoCure's conference call transcript? The conference call transcript for NovoCure's latest earnings report can be read online. Read Transcript How can I view NovoCure's earnings report? NovoCure's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does NovoCure generate each year? NovoCure (NASDAQ:NVCR) has a recorded annual revenue of $509.34 million. How much profit does NovoCure generate each year? NovoCure (NASDAQ:NVCR) has a recorded net income of -$207.04 million. NVCR has generated -$1.40 earnings per share over the last four quarters. What is NovoCure's EPS forecast for next year? NovoCure's earnings are expected to decrease from ($1.31) per share to ($1.58) per share in the next year. More Earnings Resources from MarketBeat Related Companies PEN Earnings GKOS Earnings BLCO Earnings INSP Earnings PRCT Earnings NVST Earnings AXNX Earnings NARI Earnings TMDX Earnings LIVN Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. This page (NASDAQ:NVCR) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
